Company news
ALX Oncology Holdings Inc. news in 2023
ALX Oncology Holdings Inc.'s news releases, calls and decks from 2023, newest first.
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
ALX Oncology Announces November Investor Conference Participation
October 31, 2023
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 9, 2023
ALX Oncology Announces Pricing of Public Offering
October 4, 2023
ALX Oncology Announces Proposed Public Offering
October 3, 2023
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 2, 2023
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 1, 2023
ALX Oncology Realigns Executive Leadership Team
September 5, 2023
ALX Oncology Announces September Investor Conference Participation
August 30, 2023
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
August 9, 2023
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
June 25, 2023
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 10, 2023
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer
May 8, 2023
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma
April 24, 2023
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer
March 12, 2023
ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
March 8, 2023
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer
February 15, 2023
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
January 4, 2023
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023